Evidence map›Paper›PMID 27782139›Full record

ArticleNature microbiology2016

Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice.

Alexandra E Livanos, Thomas U Greiner, Pajau Vangay, Wimal Pathmasiri, Delisha Stewart, Susan McRitchie, Huilin Li, Jennifer Chung, Jiho Sohn, Sara Kim and 12 more

Abstract read
In one paragraph

Article in Nature microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 2 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 2 syntheses or guidelines pooled it, 366 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Human intestinal microbiome: Role in health and disease.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024
    Review
  20. Review

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 3 countries.

Alexandra E LivanosDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Thomas U GreinerDepartment of Molecular and Clinical Medicine, University of Gothenburg, 40530 Gothenburg, Sweden.
Pajau VangayBiomedical Informatics and Computational Biology Program, University of Minnesota, Minneapolis, Minneapolis 55455, USA.
Wimal PathmasiriSystems and Translational Sciences, RTI International, Research Triangle Park, North Carolina 27709, USA.
Delisha StewartSystems and Translational Sciences, RTI International, Research Triangle Park, North Carolina 27709, USA.
Susan McRitchieSystems and Translational Sciences, RTI International, Research Triangle Park, North Carolina 27709, USA.
Huilin LiDepartments of Population Health, New York University Langone Medical Center, New York, New York 10016, USA.
Jennifer ChungDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Jiho SohnDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Sara KimDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Zhan GaoDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Cecily BarberDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Joanne KimDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Sandy NgDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Arlin B RogersDepartment of Biomedical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts 01536, USA.
Susan SumnerSystems and Translational Sciences, RTI International, Research Triangle Park, North Carolina 27709, USA.
Xue-Song ZhangDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Ken CadwellDepartment of Microbiology, New York University Langone Medical Center, New York, New York 10016, USA.ORCID http://orcid.org/0000-0002-5860-0661
Dan KnightsComputer Science and Engineering, University of Minnesota, Minneapolis, Minneapolis 55455, USA.
Alexander AlekseyenkoDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
Fredrik BäckhedDepartment of Molecular and Clinical Medicine, University of Gothenburg, 40530 Gothenburg, Sweden.
Martin J BlaserDepartments of Medicine and Microbiology, Human Microbiome Program, New York University Langone Medical Center, Medical Service, New York, New York 10016, USA.
NYU Langone Health · USRTI International · USUniversity of Minnesota · USTufts University · USUniversity of Copenhagen · DKUniversity of Gothenburg · SEVA NY Harbor Healthcare System · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
MEDICAL SCIENTIST TRAININGT32GM007308 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 1985 to 2019
$23.2M
NCI NIH HHS P30 CA016087NIGMS NIH HHS T32 GM007308
6 · The paper itself

Abstract

The early life microbiome plays important roles in host immunological and metabolic development. Because the incidence of type 1 diabetes (T1D) has been increasing substantially in recent decades, we hypothesized that early-life antibiotic use alters gut microbiota, which predisposes to disease. Using non-obese diabetic mice that are genetically susceptible to T1D, we examined the effects of exposure to either continuous low-dose antibiotics or pulsed therapeutic antibiotics (PAT) early in life, mimicking childhood exposures. We found that in mice receiving PAT, T1D incidence was significantly higher, and microbial community composition and structure differed compared with controls. In pre-diabetic male PAT mice, the intestinal lamina propria had lower Th17 and T

Indexed as

AnimalsAnti-Bacterial AgentsCholesterolDiabetes Mellitus, Type 1Drug Administration ScheduleFecesGastrointestinal MicrobiomeGene ExpressionGenetic Predisposition to DiseaseLipid MetabolismMetabolomeMiceMice, Inbred NODMucous MembraneObesityPenicillin VAnti-Bacterial AgentsCholesterolPenicillin VRNA, Ribosomal, 16S

Identifiers

PMID27782139
PMCPMC5808443
OpenAlexW2512457722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.